GlassScriptPhysician profile
Katherine A Alexander
NPI 1568879435
$99,493.75
in general payments reported to CMS, 2019-2025
65 companies · $1,713 in 2025
The $1,713 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $18K · 2022: $33K · 2023: $26K · 2024: $21K · 2025: $1,713.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $28K · Travel and Lodging: $8,677 · Food and Beverage: $8,147 · Consulting Fee: $1,981 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $700 · Education: $646.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $28,165.00 |
| Travel and Lodging | $8,677.15 |
| Food and Beverage | $8,146.59 |
| Consulting Fee | $1,981.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $700.00 |
| Education | $646.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Taiho Oncology, INC. | $35,419.49 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $16,629.00 | 2021-2025 | Opdivo, Reblozyl, Opdualag |
| Heron Therapeutics, INC. | $11,154.00 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $7,201.13 | 2021-2025 | Fruzaqla, Alunbrig, Ninlaro |
| Pfizer INC. | $6,539.27 | 2023-2025 | |
| Seagen INC. | $5,435.50 | 2021-2023 | Padcev, Tukysa |
| Astellas Pharma US INC | $4,943.65 | 2022-2024 | Padcev, Xtandi |
| Btg International INC. | $1,000.00 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $937.17 | 2021-2025 | Enhertu, Tagrisso, Lynparza |
| Eisai INC. | $840.17 | 2021-2025 | |
| Incyte Corporation | $791.53 | 2021-2025 | Jakafi, Monjuvi, Pemazyre |
| Cti Biopharma Corp. | $737.80 | 2022-2023 | Vonjo |
| Glaxosmithkline, LLC. | $684.84 | 2021-2025 | Zejula, Jemperli, Ojjaara |
| Gilead Sciences, INC. | $602.51 | 2022-2025 | Trodelvy |
| Amgen INC. | $500.81 | 2021-2022 |
Show all 65 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $499.51 | 2022-2025 | |
| Beigene USA, INC. | $470.27 | 2021-2024 | Brukinsa |
| Daiichi Sankyo INC. | $359.21 | 2021-2025 | Enhertu, Datroway |
| Merck Sharp & Dohme LLC | $327.44 | 2021-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Lilly USA, LLC | $283.60 | 2021-2025 | Jaypirca, Verzenio, Retevmo |
| Karyopharm Therapeutics INC. | $273.66 | 2021-2025 | Xpovio |
| Pharmacyclics LLC, An Abbvie Company | $263.94 | 2021-2023 | Imbruvica, Epkinly |
| Genentech USA, INC. | $261.20 | 2021-2024 | Polivy, Lunsumio, Venclexta |
| Celgene Corporation | $244.96 | 2021-2024 | Reblozyl, Pomalyst |
| Regeneron Healthcare Solutions, INC. | $210.52 | 2022-2024 | Libtayo |
| Aveo Pharmaceuticals, INC. | $210.38 | 2023-2025 | Fotivda |
| Jazz Pharmaceuticals INC. | $194.14 | 2022-2024 | |
| Sobi, INC | $181.25 | 2024-2025 | |
| Beone Medicines USA, INC. | $179.72 | 2025 | Brukinsa, Tevimbra |
| Abbvie INC. | $167.63 | 2023-2025 | |
| Ipsen Biopharmaceuticals, INC | $166.06 | 2021-2025 | Onivyde, Somatuline Depot |
| Janssen Biotech, INC. | $152.07 | 2022-2024 | Rybrevant, Erleada, Carvykti |
| Array Biopharma INC | $142.14 | 2023-2025 | Braftovi, Mektovi, Lorbrena |
| Tersera Therapeutics LLC | $141.42 | 2022-2025 | Zoladex |
| Geron Corporation | $128.64 | 2024-2025 | Rytelo |
| Coherus Oncology, INC. | $97.57 | 2021-2022 | |
| Genmab U.S., INC. | $88.85 | 2023-2025 | Epkinly, Tivdak |
| Pharmacosmos Therapeutics INC. | $84.95 | 2023-2025 | Monoferric, Cosela |
| Servier Pharmaceuticals LLC | $74.93 | 2022-2024 | |
| Emd Serono, INC. | $73.93 | 2021-2024 | Bavencio |
| Stemline Therapeutics INC. | $71.93 | 2023-2024 | Orserdu, Elzonris |
| Amneal Pharmaceuticals LLC | $68.76 | 2024-2025 | Alymsys, Avastin |
| Genzyme Corporation | $54.85 | 2022 | |
| G1 Therapeutics, INC. | $51.11 | 2022-2023 | Cosela |
| Blueprint Medicines Corporation | $48.92 | 2021-2024 | Ayvakit |
| Springworks Therapeutics, INC. | $48.11 | 2024 | Ogsiveo |
| Exelixis INC. | $44.97 | 2025 | Cabometyx |
| Adc Therapeutics America, INC. | $42.54 | 2022-2024 | |
| Pharmaessentia USA Corporation | $40.79 | 2023 | Besremi |
| Alexion Pharmaceuticals, INC. | $38.36 | 2022-2023 | Ultomiris |
| Kite Pharma, INC. | $31.96 | 2025 | Yescarta |
| Kyowa Kirin, INC. | $27.90 | 2023-2024 | Poteligeo |
| Tempus Ai, INC | $25.36 | 2025 | Xt Cdx |
| Bayer Healthcare Pharmaceuticals INC. | $22.31 | 2023 | |
| Dendreon Pharmaceuticals LLC | $20.81 | 2023 | Provenge |
| Sun Pharmaceutical Industries INC. | $20.78 | 2024 | |
| Agios Pharmaceuticals, INC. | $17.50 | 2024 | Pyrukynd |
| Spectrum Pharmaceuticals INC. | $16.90 | 2023 | Rolvedon |
| Acrotech Biopharma INC. | $16.89 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.64 | 2023 | Gilotrif |
| Acceleron Pharma, INC. | $16.27 | 2021 | |
| Amag Pharmaceuticals, INC. | $15.50 | 2021 | |
| Immunogen, INC. | $15.20 | 2023 | Elahere |
| Dova Pharmaceuticals | $12.51 | 2021 | |
| Puma Biotechnology, INC. | $12.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Alexander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.